D. Boral Capital Cuts Can-Fite BioPharma (NYSE:CANF) Price Target to $4.00

Can-Fite BioPharma (NYSE:CANF) had its price objective reduced by D. Boral Capital from $11.00 to $4.00 in a research report sent to investors on Wednesday,Benzinga reports. They currently have a buy rating on the stock.

CANF has been the subject of several other reports. HC Wainwright reaffirmed a “buy” rating and issued a $2.50 target price on shares of Can-Fite BioPharma in a report on Tuesday, November 4th. Zacks Research raised Can-Fite BioPharma to a “hold” rating in a research report on Thursday, November 6th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $3.25.

Can-Fite BioPharma Stock Up 0.8%

Can-Fite BioPharma stock opened at $0.25 on Wednesday. The company has a market capitalization of $6.60 million, a PE ratio of -0.14 and a beta of 0.98. Can-Fite BioPharma has a 12-month low of $0.25 and a 12-month high of $2.33. The firm’s fifty day moving average is $0.38 and its 200 day moving average is $0.67.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Sabby Management LLC lifted its position in Can-Fite BioPharma Ltd. (NYSE:CANF) by 80.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,406,050 shares of the company’s stock after purchasing an additional 626,306 shares during the quarter. Can-Fite BioPharma accounts for about 1.0% of Sabby Management LLC’s holdings, making the stock its 6th largest holding. Sabby Management LLC owned approximately 39.72% of Can-Fite BioPharma worth $871,000 at the end of the most recent reporting period. 21.00% of the stock is owned by institutional investors and hedge funds.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company headquartered in Petah Tikva, Israel, that focuses on the development of small molecule drugs for the treatment of inflammatory, oncology and liver diseases. Established in 1994, the company leverages its proprietary technology platform centered on modulating the adenosine receptor system to advance novel therapeutic candidates. Can-Fite’s research and development efforts are directed toward addressing significant unmet medical needs in autoimmune and cancer indications.

The company’s lead product candidates include piclidenoson (CF101) and namodenoson (CF102).